Vaxess Technologies

At Vaxess, we're developing a transdermal patch technology to transform home delivery of therapies like GLP-1, and vaccines (both mRNA and non-mRNA). Watch the video below to see how Vaxess's MIMIX patch and applicator is designed to be needle-free, painless for patients, and easy to administer from the comfort of their homes. https://lnkd.in/dZ3mzS4V

Thank you Bio-IT World World for sharing Vaxess's NIH grant announcement! https://lnkd.in/e_XCqw-j

We’re thrilled to announce that Vaxess has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institute of Health (NIH). Vaxess will use this funding to build on the company’s existing efforts in GLP-1, exploring how the Vaxess MIMIX transdermal patch platform can enable simple and effective GLP-1 RA at-home delivery for people with type 2 diabetes (T2D). Read more about today’s news in the release below: https://lnkd.in/eybmhfUv

In BioPharma-Reporter’s latest Women in Science Q&A, Vaxess CEO Rachel Sha shares her career journey, why she’s passionate about the work we’re doing at Vaxess, and advice for women interested in pursuing a career in the sciences. Read the full Q&A below: https://lnkd.in/eNdaF2-j

It was an honor to keynote this week's inaugural Boston Biotech Investor Day. I focused on the lessons I've learned over the course of my career to-date, which has spanned a variety of roles at large biopharma companies, startup investing and advising, and now leading a startup as CEO of Vaxess. In the next few weeks, I plan to summarize the talk and share it here. Thank you to BioLabs, LabCentral, and The Engine Accelerator for hosting! I look forward to attending the event again next year. (photo courtesy of LabCentral)

We’re thrilled to announce that Peter Kolchinsky, PhD, co-founder and managing partner at RA Capital Management, has joined Vaxess’s board of directors. “The benefits of Vaxess’s technology go well beyond addressing the very common and real fear that many of us have of needles,” said Kolchinsky. “Imagine if important medicines like GLP-1s could be administered via a once-weekly patch that you apply to your skin and throw away after a few minutes, with no need for a sharps container or refrigeration. In the case of vaccines, imagine getting a booster patch sent in the mail, sparing you from having to travel to a clinic for a shot. Vaxess is truly reimagining what a transdermal patch can do.” Read more about today's news below. https://lnkd.in/e5QSmVbq

Congratulations to The Engine on raising a $398 million third fund. Vaxess was honored to be mentioned as an Engine portfolio company in the recent Forbes feature about the news. "Vaxess, for example, is working on patches that deliver vaccines and biologics in a way that reduces the need for cold chains and syringes." https://lnkd.in/eQddsdky

Congratulations to the entire Vaxess team for the publication of our first phase 1 clinical trial results for the MIMIX skin patch for vaccines and therapeutics. This specific clinical trial evaluated the “safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults.” You can read the full paper below, which details the clinical trial’s success — namely, “the MIMIX MAP platform is safe, well tolerated and elicits robust antibody responses.” The Vaxess team looks forward to continuing to apply the MIMIX skin patch to a range of additional vaccines and therapeutics. https://lnkd.in/gJ98DawK

Vaxess CEO, Rachel Sha, had the pleasure of meeting and learning from many of the amazing thought leaders and pioneers in the biotech space. Thanks to Biotechnology Innovation Organization for hosting another great convention this week!

Thank you to Pulse 2.0 for spreading the good news about our recent funding announcement! https://lnkd.in/eQDXCN6u